Timing of use of anti-tumor necrosis factor (anti-TNF) medication perioperatively.
| Anti-TNF | Stop Time, weeks ± SD, n = 71 | Restart Times, weeks ± SD, n = 23 |
|---|---|---|
| Etanercept (n = 59) | 2.4 ± 2.4 (n = 39) | 2.1 ± 1.1 (n = 15) |
| Standard dosing: weekly (t½ = 3–5.5 days) | range 1–14 | range 1–4 |
| Golimumab (n = 2) | 8 (n = 1) | 1.5 (n = 1) |
| Standard dosing: monthly (t½ = 7–20 days) | range NA | range NA |
| Adalimumab (n = 25) | 5 ± 5.6 (n = 20) | 2 ± 1 (n = 3) |
| Standard dosing: every 2 weeks (t½ = 10–20 days) | range 1–24 | range 1–3 |
| Infliximab (n = 18) | 4.8 ± 2.2 (n = 11) | 4.4 ± 1.8 (n = 4) |
| Standard dosing: every 4–8 weeks (t½ = 7–12 days) | range 2–9 | range 2–4 |
t½: half-life. NA: not available.